Traders should monitor upcoming catalysts: NDA submission for deucrictibant IR capsule (H1 2026) and topline data from CHAPTER-3 (Q3 2026), which are more likely to move the stock than this validation study.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 11 $27.43entry
- T+1 · 8mo ago −3.83%α −2.34% · $26.38
- T+5 · 8mo ago −4.59%α −2.40% · $26.17
- T+20 · 7mo ago −1.31%α −1.84% · $27.07
- T+60 · 6mo ago +9.88%α −1.64% · $30.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris announced the publication of a real-world study validating patient-reported outcome measures (PGI and AMRA) used in clinical trials for on-demand treatment of hereditary angioedema (HAE), supporting the endpoint hierarchy in its ongoing Phase 3 RAPIDe-3 trial of deucrictibant. The findings reinforce the patient-centric design of the trial and may influence future HAE treatment assessments.
Key Facts
- Study validates PGI and AMRA instruments as reliable tools for assessing patient experience during HAE attacks.
- Findings support the hierarchical endpoint structure in the Phase 3 RAPIDe-3 trial of oral deucrictibant for on-demand HAE treatment.
- End of Progression™ was identified as the first meaningful milestone, followed by symptom relief and resolution.
- Deucrictibant has orphan drug designation in the U.S., EU, and Switzerland for bradykinin-mediated angioedema.
- NDA submission for deucrictibant immediate-release capsule expected in first half of 2026; CHAPTER-3 topline data expected Q3 2026.
Financial Impact
No direct financial impact disclosed; supports clinical development pathway without immediate revenue or cost implications.
Risk Factors
- Regulatory uncertainty regarding approval of deucrictibant despite validated endpoints.
- Clinical trial results may not replicate prior efficacy in larger studies.
- Competition from existing and emerging HAE therapies could limit market adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253609 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers